John Garner

PLGA-Rhodamine from PolySciTech used for development of drug-delivery system as potential treatment of Peritoneal Mesothelioma

Blog Post created by John Garner on Jun 28, 2016

PolySciTech Division of Akina, Inc. ( provides a wide array of biodegradable polymers including fluorescently conjugated PLGA’s used for nanoparticle tracking. Recently, researchers used Poly(lactide-co-glycolide)-Rhodamine B (PolyVivo# AV011) from PolySciTech as part of a nanoparticle tracking system in the development of paclitaxel loaded nanoparticles for targeted drug delivery to mesothelioma. This research has the potential to treat a deadly disease. Read more here: Liu, Rong, Aaron H. Colby, Denis Gilmore, Morgan Schulz, Jialiu Zeng, Robert F. Padera, Orian Shirihai, Mark W. Grinstaff, and Yolonda L. Colson. "Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma." Biomaterials 102 (2016): 175-186.


  “Abstract: The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new approaches that concentrate drug at the tumor for a prolonged period of time yielding enhanced antitumor efficacy and improved metrics of treatment success. A paclitaxel-loaded pH-responsive expansile nanoparticle (PTX-eNP) system is described that addresses two unique challenges to improve the outcomes for peritoneal mesothelioma. First, following intraperitoneal administration, eNPs rapidly and specifically localize to tumors. The rate of eNP uptake by tumors is an order of magnitude faster than the rate of uptake in non-malignant cells; and, subsequent accumulation in autophagosomes and disruption of autophagosomal trafficking leads to prolonged intracellular retention of eNPs. The net effect of these combined mechanisms manifests as rapid localization to intraperitoneal tumors within 4 h of injection and persistent intratumoral retention for >14 days. Second, the high tumor-specificity of PTX-eNPs leads to delivery of greater than 100 times higher concentrations of drug in tumors compared to PTX alone and this is maintained for at least seven days following administration. As a result, overall survival of animals with established mesothelioma more than doubled when animals were treated with multiple doses of PTX-eNPs compared to equivalent dosing with PTX or non-responsive PTX-loaded nanoparticles. Keywords: Mesothelioma; Nanoparticle; Drug delivery; Paclitaxel; Autophagosome; Tumor localization”